Drug search by name

Insulin glargine and lixisenatide and Renal/liver disease

Result of checking the interaction of drug Insulin glargine and lixisenatide and disease Renal/liver disease for safety when used together.

Check result:

Insulin glargine and lixisenatide <> Renal/liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis. Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.

References:

"Product Information. Novolog (insulin aspart)" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
"Product Information. Lantus (insulin glargine)" Aventis Pharmaceuticals, Swiftwater, PA.

Insulin glargine and lixisenatide

Generic Name: insulin glargine / lixisenatide

Brand Name: Soliqua 100/33

Synonyms: Insulin Glargine and Lixisenatide

What is Insulin glargine and lixisenatide?